GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » HeraMED Ltd (ASX:HMD) » Definitions » ROCE %

HeraMED (ASX:HMD) ROCE % : -48.13% (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is HeraMED ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. HeraMED's annualized ROCE % for the quarter that ended in Dec. 2024 was -48.13%.


HeraMED ROCE % Historical Data

The historical data trend for HeraMED's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeraMED ROCE % Chart

HeraMED Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
Get a 7-Day Free Trial -107.73 -283.93 -167.24 -203.77 -226.70

HeraMED Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -103.77 -193.22 -378.69 -456.81 -48.13

HeraMED ROCE % Calculation

HeraMED's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-8.593/( ( (4.418 - 2.253) + (7.08 - 1.664) )/ 2 )
=-8.593/( (2.165+5.416)/ 2 )
=-8.593/3.7905
=-226.70 %

HeraMED's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=-2.28/( ( (6.988 - 2.929) + (7.08 - 1.664) )/ 2 )
=-2.28/( ( 4.059 + 5.416 )/ 2 )
=-2.28/4.7375
=-48.13 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HeraMED  (ASX:HMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


HeraMED ROCE % Related Terms

Thank you for viewing the detailed overview of HeraMED's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


HeraMED Business Description

Traded in Other Exchanges
N/A
Address
201, 697 Burke Road, Suite 4, Camberwell, VIC, AUS, 3124
HeraMED Ltd is engaged in developing, connected pregnancy monitoring solutions for home and professional use. It has developed a foetal heartbeat monitor called HeraBEAT which is a medical-grade, clinically-validated, smart and connected Ultrasound Foetal Doppler device predominantly for use by an expectant mother to self-monitor her foetus' heart rate (FHR). It is also focused on the commercialization and deployment of its HeraCARE pregnancy monitoring solution. Geographically, the company generates a majority of its revenue from the United States of America followed by Australia and Israel.

HeraMED Headlines

No Headlines